(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
(Alliance News) - Evgen Pharma on Tuesday said Non-Executive Chair Barry Clare will retire at its next board meeting, and announced the hiring of interim Chief Financial Officer Toni Hanninen. Read More
(Alliance News) - Faron Pharmaceuticals Ltd on Tuesday said its interim loss widened on higher costs but saw shares soar after it gained a US Food & Drug Administration orphan drug designation for Bexmarilimab. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued Thursday and not separately reported by Alliance News: Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued Friday and not separately reported by Alliance News: Read More
(Alliance News) - Faron Pharmaceuticals Ltd on Monday said further data from its Phase I/II MATINS study of bexmarilimab has indicated the efficacy and safety of the immunotherapy in solid tumours. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More
(Alliance News) - Faron Pharmaceuticals Ltd on Wednesday said it has appointed James O'Brien as its new chief financial officer, effective from Monday next week, succeeding Toni Hanninen. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Thursday and not separately reported by Alliance News: Read More
Faron Pharmaceuticals Ltd - Turku, Finland-based biopharmaceutical drug discovery and development company - Raises EUR12.0 million via placing of 3.7 million shares at the issue price of EUR3.25 each. Faron says that with these proceeds and the current level of activity, it has sufficient working capital into the third quarter of 2023. Read More
(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News: Read More
(Alliance News) - Faron Pharmaceuticals Ltd on Monday said it was encouraged by promising early data from trials for its investigative precision immunotherapy, which aims to provide permanent immune stimulation for difficult-to-treat cancers by targeting myeloid cell function. Read More